Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Puma has been focused on developing the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. Puma believes that neratinib has clinical applications in the treatment of several other cancers as well, including non-small cell lung cancer and other solid tumor types that over-express or have a mutation in HER2. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma commenced commercial sales of the drug in 2017 and it is marketed in the United States as NERLYNX® tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. Commercial sales commenced in the European Union in 2019. Puma has entered into additional exclusive license agreements with various parties to commercialize NERLYNX in regions outside the United States, including the European Union, Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma plans to continue to pursue the commercialization of NERLYNX outside the United States. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib has been tested in clinical trials in patients with metastatic cancers including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Puma initially intends to focus the development of alisertib on the treatment of patients with metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer and small cell lung cancer. Alan H. Auerbach has served as Chairman of the Board, CEO and President of Puma Biotechnology, Inc. since he founded the Company in 2010. Prior to Puma, Mr. Auerbach served as CEO, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from its inception in 2003 until its acquisition by Johnson & Johnson in July 2009. From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of J&J), providing leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone (Zytiga) was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the EU in September 2011. Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and mid-cap biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific and clinical due diligence, and selected biotechnology companies followed by the company. In 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-cap biotechnology companies. Prior to his work as a securities analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Puma Biotechnology, Inc., founded in 2010, is headquartered in Los Angeles, California. Additional information may be found at https://www.pumabiotechnology.com. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔

Meta Tags

Title	Puma Biotechnology
Description	Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Puma has been focused on developing the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. Puma believes that neratinib has clinical applications in the treatment of several other cancers as well, including non-small cell lung cancer and other solid tumor types that over-express or have a mutation in HER2. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma commenced commercial sales of the drug in 2017 and it is marketed in the United States as NERLYNX® tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. Commercial sales commenced in the European Union in 2019. Puma has entered into additional exclusive license agreements with various parties to commercialize NERLYNX in regions outside the United States, including the European Union, Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma plans to continue to pursue the commercialization of NERLYNX outside the United States. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib has been tested in clinical trials in patients with metastatic cancers including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Puma initially intends to focus the development of alisertib on the treatment of patients with metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer and small cell lung cancer. Alan H. Auerbach has served as Chairman of the Board, CEO and President of Puma Biotechnology, Inc. since he founded the Company in 2010. Prior to Puma, Mr. Auerbach served as CEO, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from its inception in 2003 until its acquisition by Johnson & Johnson in July 2009. From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of J&J), providing leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone (Zytiga) was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the EU in September 2011. Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and mid-cap biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific and clinical due diligence, and selected biotechnology companies followed by the company. In 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-cap biotechnology companies. Prior to his work as a securities analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Puma Biotechnology, Inc., founded in 2010, is headquartered in Los Angeles, California. Additional information may be found at https://www.pumabiotechnology.com. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
Keywords	Puma Biotechnology, biotechnology, nerlynx, neratinib, neratinib tablets, breast cancer, early stage, metastatic, drug development, pb272, clinical trials, oncology, her2+, biopharmaceutical, in-licensing, cancer treatment, oncology, extended adjuvant therapy, non-small cell lung cancer, biliary cancer, ExteNET, SUMMIT, FB-10 , CONTROL, NALA, tyrosine kinase inhibitor, TBCRC-022, HER2-mutated, EGFR, EGFR exon 18, EGFR exon 18-mutant, HER-Seq, alisertib, aurora kinase A, adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A, inhibitor of aurora kinase A, disruption of mitosis, apoptosis of rapidly proliferating tumor cells, apoptosis of tumor cells, breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, acute myeloid leukemia, metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer, HER2-negative breast cancer, ER-positive breast cancer,

Server Information

Website	www.pumabiotechnology.com
Host IP	97.74.103.44 173.201.71.44
Location	United States

Related Websites

                    Site
                    Rank
                

More to Explore

adstatic.com

attac.de

shellpointmortgageservicing.com

pumabiotechnology.com Valuation

US$8,817

Last updated: January 13, 2024

pumabiotechnology.com has global traffic rank of 793,895. pumabiotechnology.com has an estimated worth of US$ 8,817, based on its estimated Ads revenue. pumabiotechnology.com receives approximately 10 unique visitors each day. Its web server is located in United States, with IP address 97.74.103.44. According to Statvoo, pumabiotechnology.com is trusted to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$8,817
Daily Ads Revenue	US$6
Monthly Ads Revenue	US$184
Yearly Ads Revenue	US$2,204
Daily Unique Visitors	10
Note: All traffic and earnings values are estimates.

Traffic Ranks

Global Rank	793,895
Delta (90 Days)	0
Most Popular In Country	N/A
Country Rank	N/A

DNS Records

Host	Type	IP	Nameserver
pumabiotechnology.com	A	97.74.103.44	ns67.domaincontrol.com.
pumabiotechnology.com	A	173.201.71.44	ns68.domaincontrol.com.

Domain Name Misspellings

oumabiotechnology.com	lumabiotechnology.com
pymabiotechnology.com	phmabiotechnology.com
pjmabiotechnology.com	pkmabiotechnology.com
pimabiotechnology.com	punabiotechnology.com
puhabiotechnology.com	pujabiotechnology.com
pukabiotechnology.com	pulabiotechnology.com
pumqbiotechnology.com	pumwbiotechnology.com
pumzbiotechnology.com	pumxbiotechnology.com
pumaviotechnology.com	pumafiotechnology.com
pumagiotechnology.com	pumahiotechnology.com
pumaniotechnology.com	pumabuotechnology.com
pumabjotechnology.com	pumabkotechnology.com
pumablotechnology.com	pumabootechnology.com
pumabiitechnology.com	pumabiktechnology.com
pumabiltechnology.com	pumabiptechnology.com
pumabiorechnology.com	pumabiofechnology.com
pumabiogechnology.com	pumabiohechnology.com
pumabioyechnology.com	pumabiotwchnology.com
pumabiotschnology.com	pumabiotdchnology.com
pumabiotfchnology.com	pumabiotrchnology.com
pumabiotexhnology.com	pumabioteshnology.com
pumabiotedhnology.com	pumabiotefhnology.com
pumabiotevhnology.com	pumabiotecbnology.com
pumabiotecgnology.com	pumabiotectnology.com
pumabiotecynology.com	pumabiotecunology.com
pumabiotecjnology.com	pumabiotecmnology.com
pumabiotecnnology.com	pumabiotechbology.com
pumabiotechgology.com	pumabiotechhology.com
pumabiotechjology.com	pumabiotechmology.com
pumabiotechnilogy.com	pumabiotechnklogy.com
pumabiotechnllogy.com	pumabiotechnplogy.com
pumabiotechnopogy.com	pumabiotechnooogy.com
pumabiotechnoiogy.com	pumabiotechnokogy.com
pumabiotechnomogy.com	pumabiotechnoligy.com
pumabiotechnolkgy.com	pumabiotechnollgy.com
pumabiotechnolpgy.com	pumabiotechnolory.com
pumabiotechnolofy.com	pumabiotechnolovy.com
pumabiotechnoloty.com	pumabiotechnoloby.com
pumabiotechnoloyy.com	pumabiotechnolohy.com
pumabiotechnolony.com	pumabiotechnologt.com
pumabiotechnologg.com	pumabiotechnologh.com
pumabiotechnologj.com	pumabiotechnologu.com

HTTP Headers

bytes
Upgrade, Keep-Alive
gzip
11399
text/html
Sat, 13 Jan 2024 07:38:51 GMT
"4e1b7f-d7b3-60eb205bd8984-gzip"
timeout=5
Thu, 11 Jan 2024 21:13:43 GMT
Apache
h2,h2c
Accept-Encoding

pumabiotechnology.com Whois Information

Domain Name	PUMABIOTECHNOLOGY.COM pumabiotechnology.com
Registrar	GoDaddy.com, LLC
Whois Server	whois.godaddy.com
Referral Url
Updated Date	2023-05-24 18:09:59 2023-05-24 13:09:57
Creation Date	2010-08-26 19:52:17 2010-08-26 14:52:17
Expiration Date	2024-08-26 19:52:17 2024-08-26 14:52:17
Name Servers	NS67.DOMAINCONTROL.COM NS68.DOMAINCONTROL.COM
Status	clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited clientRenewProhibited https://icann.org/epp#clientRenewProhibited clientTransferProhibited https://icann.org/epp#clientTransferProhibited clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Emails	abuse@godaddy.com
Dnssec	unsigned
Name	Registration Private
Org	Domains By Proxy, LLC
Address	DomainsByProxy.com 2155 E Warner Rd
City	Tempe
State	Arizona
Registrant Postal Code	85284
Country	US

pumabiotechnology.com valuation and analysis